SCHEMBL572094

SCHEMBL572094

O=c1c(-c2ccc(O)cc2)coc2c(O)c(O)cc(O)c12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.74
MAPT P10636 6/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
TP53 P04637 4/20 0.62
HPGD P15428 4/20 0.62
ALOX15 P16050 4/20 0.62
MEN1 O00255 4/20 0.62
NPC1 O15118 4/20 0.62
CYP3A4 P08684 4/20 0.62
RAB9A P51151 4/20 0.62
KMT2A Q03164 4/20 0.62
ESR1 P03372 3/20 0.62
ESR2 Q92731 3/20 0.62
MAPK1 P28482 3/20 0.62
CYP1A2 P05177 3/20 0.62
CYP2C9 P11712 3/20 0.62
CYP2C19 P33261 3/20 0.62
XDH P47989 2/20 0.62
EGFR P00533 2/20 0.62
ABCB1 P08183 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26071480 0.88 ALDH1A1 (0.66) ALDH1A1MAPTSMN1; SMN2TP53HPGD
SCHEMBL30851591 0.87 ALOX15 (0.59) ALDH1A1MAPTHPGDALOX15MEN1
SCHEMBL16431882 0.87 ALOX15 (0.59) ALDH1A1MAPTHPGDALOX15MEN1
SCHEMBL15853599 0.85 ALDH1A1 (1.00) ALDH1A1MAPTSMN1; SMN2TP53HPGD
Psi-Tectorigenin SCHEMBL29783038 0.82 ALDH1A1 (0.70) ALDH1A1MAPTSMN1; SMN2TP53HPGD
Psi-Tectorigenin SCHEMBL571713 0.82 ALDH1A1 (0.70) ALDH1A1MAPTSMN1; SMN2TP53HPGD
SCHEMBL20354107 0.79 ALDH1A1 (0.65) ALDH1A1MAPTSMN1; SMN2TP53HPGD
SCHEMBL30525493 0.79 MAPT (0.75) ALDH1A1MAPTSMN1; SMN2TP53HPGD
SCHEMBL28437800 0.79 XDH (0.71) ALDH1A1MAPTSMN1; SMN2TP53HPGD
SCHEMBL13279932 0.79 MAPT (0.75) ALDH1A1MAPTSMN1; SMN2TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12163004-B2 Polymer composites WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2024-12-10 US claimed
CN-116407532-A Application of 8-hydroxy genistein in preparing medicine for resisting altitude anoxia 马慧萍 2023-07-11 CN claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
CN-122055354-A Lipid compounds and related compositions and uses 波西达治疗公司 2026-05-15 CN disclosed
CN-117264776-B Aspergillus pseudoaculeatus for producing flavonol and construction method of gene editing system of aspergillus pseudoaculeatus 湖南麦肯伟科技有限公司 2025-04-25 CN disclosed
WO-2025049925-A2 LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES POSEIDA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US disclosed
US-12163004-B2 Polymer composites WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2024-12-10 US disclosed
US-20240355451-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY NESTLE SA (CH) 2024-10-24 US disclosed
WO-2024107938-A2 POLYPHENOL LIPID NANOPARTICLES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-05-23 WO disclosed
CN-118028405-A Method for converting genistein into two flavone compounds by one-step biology 南京师范大学 2024-05-14 CN disclosed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US disclosed
US-6555663-B1 Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule MILLS RANDELL LEE (US) 2003-04-29 US disclosed
JP-2002308868-A PRODUCTION METHOD FOR ISOFLAVONE COMPOUND HAVING ORTHODIHYDROXY STRUCTURE MORITA KK 2002-10-23 JP disclosed
EP-0414730-B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug MILLS RANDELL L (US) 1999-12-15 EP disclosed
US-5773592-A COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED MILLS RANDELL LEE (US) 1998-06-30 US disclosed
US-5428163-A Luminides; chemiluminescence; redox system, releasing free drug MILLS RANDELL L (US) 1995-06-27 US disclosed
EP-0414730-A4 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS 1993-06-16 EP disclosed
EP-0414730-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS Mills, Randell L. (US) 1991-03-06 EP disclosed
WO-1989009833-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS MILLS RANDELL L (US) 1989-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD ALDH1A1 61/4885MAPT 2279/4885SMN1; SMN2 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.